Moxifloxacin Krka

Moxifloxacin, the active ingredient in Moxifloxacin Krka, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections in adults, including acute bacterial sinusitis, exacerbations of chronic bronchitis, community‑acquired pneumonia, and skin and soft‑tissue infections.

GNH USA supplies Moxifloxacin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide, ensuring quality and regulatory compliance.

Moxifloxacin is indicated for bacterial infections affecting the respiratory and skin systems. - Acute bacterial sinusitis: reduces bacterial load and alleviates sinus inflammation. - Acute bacterial exacerbation of chronic bronchitis: improves symptoms and shortens disease course. - Community‑acquired pneumonia: eradicates causative pathogens and supports recovery. - Skin and skin structure infections: treats susceptible Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Abdominal pain: cramping or discomfort. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: can lead to cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile infection: severe colitis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Photosensitivity: increased skin reaction to sunlight.

Before prescribing Moxifloxacin, clinicians should evaluate patient‑specific risk factors. - Renal impairment: assess kidney function and adjust if necessary. - History of tendon disorders: avoid use in patients with prior tendon injury. - Concomitant QT‑prolonging drugs: monitor cardiac rhythm closely. - Pregnancy and lactation: reserve for situations where benefits outweigh potential risks. - Age >65 years: increased susceptibility to central nervous system effects. - Store at room temperature: keep in the original container, protect from moisture and light.

Moxifloxacin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Other fluoroquinolones: additive toxicity risk. - QT‑prolonging agents (e.g., quinidine, macrolides): may cause serious arrhythmias. - Antacids containing aluminum or magnesium: reduce moxifloxacin absorption.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: heightened risk of CNS effects. - Theophylline: possible increase in serum theophylline levels.